Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL93 in Advanced or Metastatic Solid Tumors
NCT04671875Phase 1Recruiting
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Apr 2021
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MIL93 in solid tumor, gastric cancer (GC), gastroesophageal junction adenocarcinoma and 1 more (4 arms), sponsored by Beijing Tianguangshi Pharmaceutical Technology. Primary endpoint: Percentage of Participants with Adverse Events up to 1 year. Started Apr 2021; status: recruiting.
02
Drugs
MIL93
03
Conditions
solid tumorgastric cancer (GC)gastroesophageal junction adenocarcinomapancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04671875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671875.